SomantiX B.V. is a Dutch biotech company focusing on the identification and development of new angiogenesis inhibitors for the treatment of solid cancers through targeting of tumor blood vessels. Somantix’ screening platform in combination with the binder generation technologies allows validation of new therapeutic targets and development of new cancer medicines.
Looking for a particular SomantiX BV employee's phone or email?
The SomantiX BV annual revenue was $1 million in 2026.
1 people are employed at SomantiX BV.
SomantiX BV is based in Utrecht, Utrecht.
The NAICS codes for SomantiX BV are [541, 54, 5417].
The SIC codes for SomantiX BV are [283, 28].